| |
|
|
|
|
|
|
|||
|
Blood, 1 December 2007, Vol. 110, No. 12, pp. 4022-4029. Prepublished online as a Blood First Edition Paper on August 24, 2007; DOI 10.1182/blood-2007-04-082040.
NEOPLASIA Submicroscopic bone marrow involvement in isolated extramedullary relapses in childhood acute lymphoblastic leukemia: a more precise definition of "isolated" and its possible clinical implications, a collaborative study of the Resistant Disease Committee of the International BFM study group1 Department of Pediatric Oncology/Hematology, Charité Medical University Berlin, Berlin, Germany; 2 Laboratoire de Biochimie Génétique–Département de Génétique, Hôpital Robert Debré, Paris, France; 3 Department of Pediatric Hematology/Oncology, 2nd Medical School, Charles University, Prague, Czech Republic; 4 Department of Pediatric Hematology/Oncology, University Medical Center Hamburg, Eppendorf, Germany; 5 Department of Pediatrics, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany; and 6 Service d'Hématol-immunologie pédiatrique, Hôpital Robert Debré, Paris, France
This study investigates the extent of bone marrow (BM) involvement at diagnosis of apparent isolated extramedullary (AIEM) relapses of childhood acute lymphoblastic leukemia (ALL) and its relation to prognosis. Sixty-four children with first AIEM relapse treated in Germany, Czech Republic, or France were included. Real-time quantitative polymerase chain reaction using T-cell receptor and immunoglobulin gene rearrangements provided a sensitive measure of submicroscopic BM involvement, which was detectable at a level of 10–4 or higher in 46 patients and less than 10–4 in 11 patients, and was nondetectable (sensitivity: 10–4) in 7 patients. In the total cohort, the probability of event-free survival (pEFS) for children with BM involvement of 10–4 or higher was 0.30 (0.09 ± SE) versus 0.60 (± 0.12) for those with less than 10–4 (P = .13). The cumulative incidence of subsequent relapse was 0.24 (± 0.01) for patients with BM involvement less than 10–4 and 0.65 (± 0.01) for those with 10–4 or higher (P = .012). Restricted to central nervous system (CNS) relapses, pEFS was 0.11 (± 0.09) for patients with BM involvement 10–4 or higher and 0.63 (± 0.17) for those with less than 10–4 (P = .053). CNS relapses were associated with a higher (
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Copyright © 2007 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||